WALTHAM, Mass., Dec. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 11, 2023, at 7:00 a.m. PT / 10:00 a.m. ET during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.
The event will include new data for both the axatilimab and revumenib programs, and members of the Syndax management team will be joined by the following key opinion leaders:
Daniel Wolff, M.D., Professor of Hematology, Department of Internal Medicine III of the University of Regensburg
Eytan M. Stein, M.D., Chief, Program for Drug Development in Leukemia, Department of Medicine, Memorial Sloan Kettering Cancer Center
Neerav N. Shukla, M.D., Chief, Pediatric Translational Medicine Service, Memorial Sloan Kettering Cancer Center
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website or directly through the meeting link here.
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com for a limited time.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.